Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509145 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
A Phase 3 study of Multiple Sclerosis, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,106
- Enrollment target
- 20
- Study locations
NCT00509145: Completed Phase 3 study of Multiple Sclerosis, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00509145 is a Phase 3 study of Multiple Sclerosis that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 1,106 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509145, a Phase 3 study of Multiple Sclerosis, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,106 participants
- Enrollment target
- 20
- Study locations
Study Summary
Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
Primary Outcome
A relapse was defined as the appearance of at least one new neurological abnormality or the reappearance of at least one previously observed neurological abnormalities lasting greater than or equal to 48 hours and immediately preceded by an improving neurological state of greater than or equal to 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with one or more of
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Laquinimod
Study Locations (20)
Colorado
- Teva Investigational Site 1090 - Centennial
- Teva Investigational Site 1088 - Fort Collins
New York
- Teva Investigational Site 1082 - New York
- Teva Investigational Site 1079 - Rochester
Pennsylvania
- Teva Investigational Site 1100 - Hershey
- Teva Investigational Site 1087 - Philadelphia
Arizona
- Teva Investigational Site 1076 - Phoenix
Connecticut
- Teva Investigational Site 1094 - New Haven
Illinois
- Teva Investigational Site 1102 - Northbrook
Indiana
- Teva Investigational Site 1081 - Fort Wayne
Iowa
- Teva Investigational Site 1083 - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,106 participants |
| Start Date | 2007-11-13 |
| Est. Completion | 2010-11-08 |
| Phase | Phase 3 |
What the finished NCT00509145 record still lists
NCT00509145 is an interventional study that assigns participants to a tested intervention. Its 1,106 participants enrollment target places it among the larger protocols in the corpus, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00509145 names 20 study sites across 17 states, led by Colorado, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00509145 about?
NCT00509145 is a clinical study titled "Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)". Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
What is the current status of trial NCT00509145?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,106 participants. The study started on 2007-11-13. Estimated completion is 2010-11-08.
What conditions does trial NCT00509145 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00509145?
The interventions under investigation include: Placebo (OTHER), Laquinimod (DRUG).
Who is sponsoring clinical trial NCT00509145?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00509145 being conducted?
This trial has 20 study locations across Arizona, Colorado, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00509145's enrollment target sits among peer trials
1,106 24th of 315 higher than 292 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI